Literature DB >> 7669943

Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma.

B A Teicher1, N P Dupuis, Y Emi, M Ikebe, Y Kakeji, K Menon.   

Abstract

Tissue oxygen tensions were measured in the rat 9L gliosarcoma under conditions of normal air breathing or carbogen breathing and after intravenous administration of a hemoglobin solution with air breathing or carbogen breathing. Administration of the hemoglobin decreased the level of hypoxia in the tumors. Treatment of the animals with the antiangiogenic combination of TNP-470 and minocycline also increased tumor oxygenation compared with untreated controls. Treatment with the antiangiogenic agents along with administration of the hemoglobin solution/carbogen breathing decreased the hypoxic fraction (% pO2 readings < or = 5 mmHg) from 71 % to 30%. Treatment of the tumor-bearing animals with BCNU or adriamycin modestly reduced hypoxia in the tumors, while treatment with fractionated radiation markedly increased hypoxia in the tumors. Tumor growth delay was used to assess the response of the subcutaneous tumor to the various treatment combinations. There was a strong correlation between increased therapeutic response and decreased tumor hypoxia. Tumor growth delay from BCNU increased from 5.3 days to 16.4 days with TNP-470/-minocycline/hemoglobin solution/carbogen. Similarly, the tumor growth delay from adriamycin increased from 3.9 days to 17.0 days with TNP-470/minocycline/hemoglobin solution/carbogen. Finally, the tumor growth delay from fractionated radiation increased from 4.8 days to 13.3 days with TNP-470/minocycline/hemoglobin solution/carbogen. When etanidazole was added to the complete radiation regimen, the tumor growth delay increased further to 20.5 days. These data show that the addition of non-toxic agents that increase tumor oxygenation to cytotoxic therapies can markedly increase therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669943

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  4 in total

1.  Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the SGK1 Gene Are Associated with Poorer Survival.

Authors:  Steven Lehrer; Peter H Rheinstein; Kenneth E Rosenzweig
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

Review 2.  Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Authors:  Michael E Salacz; Richard E Kast; Najmaldin Saki; Ansgar Brüning; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

Review 3.  Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?

Authors:  Ruben S A Goedegebuure; Leonie K de Klerk; Adam J Bass; Sarah Derks; Victor L J L Thijssen
Journal:  Front Immunol       Date:  2019-01-14       Impact factor: 7.561

Review 4.  Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.

Authors:  Sara Alcorn; Amanda J Walker; Nishant Gandhi; Amol Narang; Aaron T Wild; Russell K Hales; Joseph M Herman; Danny Y Song; Theodore L Deweese; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.